Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas

Neha Mehta-Shah, MD, Peter A. Riedell, MD, Nancy L. Bartlett, MD, Amanda F Cashen, MD, Brad S. Kahl, MD, Todd A Fehniger, MD PhD, Chaz Moreno, Jingxia Liu, MS, PhD, Kenneth R. Carson, MD PhD

Blood (2019) 134 (Supplement_1): 1550.

https://doi.org/10.1182/blood-2019-124185

Published: 2019

Journal Articles

A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies

Jennifer A. Woyach, MD, Ian W. Flinn, MD PhD, Deborah M. Stephens, Farrukh T. Awan, MD MS, Kerry A. Rogers, MD, Sean D. Reiff, Ron E. Savage, Sudharshan Eathiraj, Lyndsey A. Szuszkiewicz, Kate Tith, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 3136.

https://doi.org/10.1182/blood-2018-99-116338

Published: 2018

Journal Articles

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Mahesh Swaminathan, MD, Hagop M. Kantarjian, MD, Naval Daver, MD, Gautam Borthakur, MD, Maro Ohanian, DO, Tapan Kadia, MD, Courtney D. DiNardo, MDMSc, Nitin Jain, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, William G Wierda, MD PhD, Farhad Ravandi, MBBS, Maria Rhona Pinsoy, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 723.

https://doi.org/10.1182/blood.V130.Suppl_1.723.723

Published: 2017

Journal Articles

Use of Hemoglobin Based Oxygen Carrier HBOC-021 (Hemopure) As a Bridge during Emergencies in Patients Unable to Receive Blood Products: Experience at a Tertiary Care Center

Shahla Bari, MD, Marina Rabinovich, PharmD, BCPS, Marjorie Curry, PharmD, BCOP, Sanjay Raj Jain, MD PhD, Lorraine Cafuir, MD

Blood (2017) 130 (Supplement 1): 4926.

https://doi.org/10.1182/blood.V130.Suppl_1.4926.4926

Published: 2017

Journal Articles

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Waleed Abdelall, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Keyur P. Patel, MD PhD, Elias J. Jabbour, MD, Naval G. Daver, MD, Tapan Kadia, MD, Rosilyn A. Gborogen, RN, Marina Konopleva, MD PhD, Farhad Ravandi, MD, Michael Andreef, MD PhD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 1642.

https://doi.org/10.1182/blood.V128.22.1642.1642

Published: 2016

Journal Articles

Rivaroxaban Prophylaxis in Severe Congenital Protein C Deficiency

Gabriel Salinas Cisneros, MD, Ziad Khatib, MD

Blood (2016) 128 (22): 4945.

https://doi.org/10.1182/blood.V128.22.4945.4945

Published: 2016

Journal Articles

The Epidemiology and Clinical Associations of Stroke in Patients with Acute Myeloid Leukemia: A Review of 10,972 Admissions from the 2012 National Inpatient Sample

Taeha Kim, MD, Joseph Shatzel, MD, Harley Friedman, MD, Frederick Lansigan, MD

Blood (2015) 126 (23): 1314.

https://doi.org/10.1182/blood.V126.23.1314.1314

Published: 2015

Journal Articles

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies

Catherine Thieblemont, MD PhD, Anastasios Stathis, MD, Giorgio Inghirami, MD, Lionel Karlin, Franck Morschhauser, MD PhD, Mary Gleeson, FRCPath, Florence Broussais, MD, Sandy Amorim, MD, Gilles Salles, MDPhD, Thierry Facon, MD, David Cunningham, FMedSci, Norbert Vey, MD PhD, Fabrice Bourdel, MSc, Patrice Herait, MD, Emanuele Zucca, MD

Blood (2014) 124 (21): 4417.

https://doi.org/10.1182/blood.V124.21.4417.4417

Published: 2014

Journal Articles

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Gautam Borthakur, MD, Hagop M. Kantarjian, Susan O'Brien, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Naval Daver, MD, Tapan M. Kadia, MD, Rosilyn Gborogen, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2014) 124 (21): 388.

https://doi.org/10.1182/blood.V124.21.388.388

Published: 2014

Journal Articles

Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Irene M. Ghobrial, MD, Erica N Boswell, BS, Stacey Chuma, BSN, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, PharmD, BCOP, Diane Warren, Patrick Mostyn, Farzana Masood, Paul G. Richardson, MD, Steven Peter Treon, MD, MA, PhD, Jeffrey Matous, MD

Blood (2013) 122 (21): 4402.

https://doi.org/10.1182/blood.V122.21.4402.4402

Published: 2013

Journal Articles

Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Irene M. Ghobrial, MD, Erica N Boswell, BS, Ranjit Banwait, MA, Tiffany Poon, BS, Amanda Donovan, BS, Stacey Chuma, BSN, Janet Kunsman, NP, Diane Warren, Meghan Bagshaw, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Steven Treon, MD, PhD

Blood (2011) 118 (21): 2705.

https://doi.org/10.1182/blood.V118.21.2705.2705

Published: 2011

Journal Articles

Reversible Posterior Leukoencephalopathy Syndrome (RPLS) Complicating Biologic and Small-Molecule Therapies for Cancer.

Robert C. Kane, MD, Robert G. Pratt, Pharm.D., Susan Lu, R.Ph, Ann T. Farrell, MD

Blood (2007) 110 (11): 3341.

https://doi.org/10.1182/blood.V110.11.3341.3341

Published: 2007

Journal Articles

Hereditary stomatocytosis: membrane and metabolism studies

WC Jr Mentzer, WB Smith, J Goldstone, SB Shohet

Blood (1975) 46 (5): 659–669.

https://doi.org/10.1182/blood.V46.5.659.659

Published: 1975

NARROW

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas

A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Use of Hemoglobin Based Oxygen Carrier HBOC-021 (Hemopure) As a Bridge during Emergencies in Patients Unable to Receive Blood Products: Experience at a Tertiary Care Center

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Rivaroxaban Prophylaxis in Severe Congenital Protein C Deficiency

The Epidemiology and Clinical Associations of Stroke in Patients with Acute Myeloid Leukemia: A Review of 10,972 Admissions from the 2012 National Inpatient Sample

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies

The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial

Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia

Reversible Posterior Leukoencephalopathy Syndrome (RPLS) Complicating Biologic and Small-Molecule Therapies for Cancer.

Hereditary stomatocytosis: membrane and metabolism studies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only